<SEC-DOCUMENT>0001140361-23-050021.txt : 20231027
<SEC-HEADER>0001140361-23-050021.hdr.sgml : 20231027
<ACCEPTANCE-DATETIME>20231027200135
ACCESSION NUMBER:		0001140361-23-050021
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20231027
FILED AS OF DATE:		20231027
DATE AS OF CHANGE:		20231027

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GNI Group Ltd.
		CENTRAL INDEX KEY:			0001958461

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231356946

	BUSINESS ADDRESS:	
		STREET 1:		NIHONBASHI-HONCHO YS BLDG 3F
		STREET 2:		2-2-2 NIHONBASHI-HONCHO, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-0023
		BUSINESS PHONE:		81-3-6214-3600

	MAIL ADDRESS:	
		STREET 1:		NIHONBASHI-HONCHO YS BLDG 3F
		STREET 2:		2-2-2 NIHONBASHI-HONCHO, CHUO-KU
		CITY:			TOKYO
		STATE:			M0
		ZIP:			103-0023

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GNI USA, Inc.
		CENTRAL INDEX KEY:			0001973229

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		231356945

	BUSINESS ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-284-0324

	MAIL ADDRESS:	
		STREET 1:		12730 HIGH BLUFF DRIVE
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>form3.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2023-10-27</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001124105</issuerCik>
        <issuerName>CATALYST BIOSCIENCES, INC.</issuerName>
        <issuerTradingSymbol>CBIO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001958461</rptOwnerCik>
            <rptOwnerName>GNI Group Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>NIHONBASHI-HONCHO YS BLDG 3F</rptOwnerStreet1>
            <rptOwnerStreet2>2-2-2 NIHONBASHI-HONCHO, CHUO-KU</rptOwnerStreet2>
            <rptOwnerCity>TOKYO</rptOwnerCity>
            <rptOwnerState>M0</rptOwnerState>
            <rptOwnerZipCode>103-0023</rptOwnerZipCode>
            <rptOwnerStateDescription>JAPAN</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001973229</rptOwnerCik>
            <rptOwnerName>GNI USA, Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>12730 HIGH BLUFF DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2>SUITE 250</rptOwnerStreet2>
            <rptOwnerCity>SAN DIEGO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92130</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>6266521</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series X Convertible Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>123400000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See footnote</value>
                    <footnoteId id="F1"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">These securities are held by GNI USA, Inc., a Delaware corporation (&quot;GNI USA&quot;), which is a wholly-owned subsidiary of GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (&quot;GNI Japan&quot;). GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI USA.</footnote>
        <footnote id="F2">Shares of Series X Convertible Preferred Stock of the Issuer, par value $0.001 per share (the &quot;Preferred Stock&quot;), are convertible into shares of the Issuer's common stock at any time at the option of the holder thereof, based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022).</footnote>
        <footnote id="F3">The Preferred Stock has no expiration date.</footnote>
    </footnotes>

    <remarks>Exhibit 24.1 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Branden Berns, as attorney-in-fact for GNI Group Ltd.</signatureName>
        <signatureDate>2023-10-27</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Branden Berns, as attorney-in-fact for GNI USA, Inc.</signatureName>
        <signatureDate>2023-10-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.1
<SEQUENCE>2
<FILENAME>ef20013560_ex24-1.htm
<DESCRIPTION>EXHIBIT 24.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using Broadridge PROfile 23.9.1.5178
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 24.1</font><br>
        </div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">POWER OF ATTORNEY</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Know all by these presents that the undersigned hereby constitutes and appoints each of Ying Luo, Thomas Wilson Eastling, Ruoyu Chen,
        Branden Berns, and Ryan Murr, and any of their substitutes, signing singly, as the undersigned&#8217;s true and lawful attorney-in-fact to:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd0c8a0e6fcac45b3ba3f7122048e1a82" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>prepare, execute in the undersigned&#8217;s name and on the undersigned&#8217;s behalf, and submit to the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) a Form ID, including amendments thereto,
                and any other document necessary or appropriate to obtain codes, passwords, and passphrases enabling the undersigned to make electronic filings with the SEC of reports require by the Securities Exchange Act of 1934 or any rule or regulation
                of the SEC;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z4e29d3433d6a40f9a62aafd780e53cc6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>execute for and on behalf of the undersigned, in the undersigned&#8217;s capacity as a director, officer and/or ten percent stockholder of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;), Forms 3,
                4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z16c4cdbb7f924424aa95b4aa64fd2d36" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any
                amendment or amendments thereto, and timely file such form with the SEC and any securities exchange or similar authority; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z1a99539629424ed9b19261afb53c141a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally
                required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such
                attorney-in-fact may approve in such attorney-in-fact&#8217;s discretion.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing
        whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution
        or revocation, hereby ratifying and confirming all that each such attorney-in-fact, or such attorney-in-fact&#8217;s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein
        granted.&#160; The undersigned also ratifies hereby any action previously taken by each attorney-in-fact that would have been authorized by this power of attorney if it has been in effect at the time such action was taken.&#160; The undersigned acknowledges
        that each attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned&#8217;s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as
        amended.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with
        respect to the undersigned&#8217;s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.</div>
      <div>&#160;</div>
      <div style="text-align: justify;">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of April 5, 2023.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z74f24160c8b2484c82e105939d33b34d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.98%; vertical-align: top;"><br>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div>GNI USA, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;"><br>
            </td>
            <td style="vertical-align: top;" colspan="2"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;"><br>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black;">
              <div>/s/ Thomas Wilson Eastling</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" id="zb8f611a2a45e4e4d87cac01899d0633b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49.98%; vertical-align: top;"><br>
            </td>
            <td style="width: 50%; vertical-align: top;" rowspan="1">
              <div>Name: Thomas Wilson Eastling</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49.98%; vertical-align: top;"><br>
            </td>
            <td style="width: 50%; vertical-align: top;" rowspan="1">
              <div>Title: Director</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
